Here are updates on spine device company stock from five key companies.
NuVasive's COO Keith Valentine sold 6,970 shares of the company's stock this past Wednesday, according to a report from The Legacy. He sold the shares at an average price of $46.96 for a total transaction value of around $327,311. A few days earlier, Canaccord Genuity set a price target on NuVasive at $51, according to a WKRB News & Analysis report.
K2M received an average broker rating score of 1.00 — a Strong Buy — from four brokers that cover the stock, according to Zacks Investment Research as reported in Ticker Report. The brokers set a 12-month consensus price of $21.
Globus Medical received a stock price of $28 from Canaccord Genuity, according to a Sleek Monkey report.
Amedica short interest shares shot up by 195 percent or 224,538 shares, according to a Rock Hill Daily report.
LDR President and CEO Christophe Lavigne sold 25,000 shares at $33.46 on Jan. 15 for a total value of $836,500, according to a report from Candle Strips.